# Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study

> **NCT01453023** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 26 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Fluticasone Furoate
- **DRUG:** Fluticasone Furoate/Vilanterol

## Key facts

- **NCT ID:** NCT01453023
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2017-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01453023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01453023, "Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01453023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*